Use of durvalumab in stage III non-small-cell lung cancer based on eligibility for the PACIFIC study.

ABSTRACT:

Background

Durvalumab following concurrent chemoradiotherapy is standard treatment for unresectable stage III non-small-cell lung cancer based on the results of the PACIFIC trial. Based on trial criteria, not all patients are eligible for durvalumab in routine clinical practice.

Methods

We evaluated eligibility for durvalumab in a real-world clinical setting and the impact of eligibility on outcomes. Consecutive patients treated with concurrent chemoradiotherapy at two tertiary centers between January 2015 and June 2022 were assessed. Clinical characteristics and outcomes were evaluated based on eligibility criteria for the PACIFIC trial.

Results

A total of 126 patients were included. Seventy patients (56%) were eligible for durvalumab. Ineligibility was associated wi

SUBMITTER: Boys E 

PROVIDER: S-EPMC9968599 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature